New tech promises to change the way drug candidates are selected at the preclinical level to enter into clinical trials—and to maximize their chances of success
Expanded capabilities in company’s Immunogenicity and Immuno-oncology QSP Simulators broaden applicability for addressing safety and efficacy challenges